Yvonne Greenstreet

Chief Executive Officer
Alnylam

Dr. Yvonne Greenstreet became Chief Executive Officer of Alnylam in January 2022, after serving as the company’s President and Chief Operating Officer from 2020 and as COO from 2016. Over more than three decades of leadership in the biopharmaceutical industry, Yvonne has made an enormous impact in enabling the development and delivery of medicines that have improved the lives of people around the world.

Prior to joining Alnylam, Yvonne was Senior Vice President and Head of Medicines Development at Pfizer, serving on the executive team leading a rapidly growing $16 billion division. Before that, she worked for 18 years at GlaxoSmithKline plc, where she served as Senior Vice President and Chief Strategy Officer for Research and Development and held various other senior positions.

Born in London and raised in Ghana and the U.K., Yvonne earned a medical degree from the University of Leeds and practiced as a clinician before earning her MBA from INSEAD and moving into the biopharmaceutical industry.

Yvonne serves on the board of directors of The American Funds and the Biomedical Sciences Careers Program and is a member of the Council on Foreign Relations.

Yvonne was awarded the Order of the British Empire (OBE) in 2025 for services to the biotechnology and life sciences industry. She was recognized as the Healthcare Businesswomen’s Association Woman of Year in 2024 for her contributions to health care and the advancement of women in the workplace.